奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆miR-21表达的影响

被引：19

作者：

严海

黄丹

胡清林

黄昊

张勇

史云天

机构：

[1] 成都医学院第一附属医院胃肠外科

来源：

现代生物医学进展 | 2017年 / 17卷 / 17期

关键词：

晚期结肠癌; 奥沙利铂; 卡培他滨; 替吉奥;

D O I：

10.13241/j.cnki.pmb.2017.17.022

中图分类号：

R735.35 [];

学科分类号：

摘要：

目的:探讨奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆微小RNA-21(mi R-21)表达水平的影响及疗效。方法:选择2013年6月至2016年6月我院接诊的90例晚期结肠癌患者,随机分为替吉奥组和卡培他滨组,每组45例。替吉奥组患者采用奥沙利铂联合替吉奥治疗,卡培他滨组患者采用奥沙利铂联合卡培他滨治疗。观察并比较两组患者治疗前后血清白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(INF-γ)及mi R-21水平变化、客观缓解率(ORR)以及不良反应。结果:治疗后,替吉奥组患者血清IL-2,TNF-α及INF-γ水平均高于卡培他滨组,而血浆mi R-21水平低于卡培他滨组,差异具有统计学意义(P<0.05);替吉奥组客观缓解率(ORR)高于卡培他滨组,而不良反应总发生率低于卡培他滨组,差异具有统计学意义(P<0.05)。结论:与卡培他滨相比,奥沙利铂联合替吉奥治疗晚期结肠癌的效果显著,可有效提高患者免疫力,抑制肿瘤发展,且不良反应较少,值得临床推广。

引用

页码：3291 / 3294

页数：4

共 8 条

[1]

Virus-Like Particles Displaying Recombinant Short-Chain Fragment Region and Interleukin 2 for Targeting Colon Cancer Tumors and Attracting Macrophages [J].

Deo, Vipin Kumar ;

Kato, Tatsuya ;

Park, Enoch Y. .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (05) :1614-1622

[2]

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial [J].

Takashi Tsuchiya ;

Sotaro Sadahiro ;

Kazuaki Sasaki ;

Ken Kondo ;

Kenji Katsumata ;

Genichi Nishimura ;

Yoshihiro Kakeji ;

Hideo Baba ;

Takayuki Morita ;

Keiji Koda ;

Seiji Sato ;

Junji Matsuoka ;

Yoshiyuki Yamaguchi ;

Hisashi Usuki ;

Chikuma Hamada ;

Susumu Kodaira ;

Shigetoyo Saji .

Cancer Chemotherapy and Pharmacology, 2014, 73 :1253-1261

[3]

miR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4 [J].

Ren, Wenhao ;

Wang, Xiaolong ;

Gao, Ling ;

Li, Shaoming ;

Yan, Xiaojing ;

Zhang, Jin ;

Huang, Chen ;

Zhang, Yincheng ;

Zhi, Keqian .

MOLECULAR AND CELLULAR BIOCHEMISTRY, 2014, 390 (1-2) :253-262

[4]

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer [J].

Oue, Naohide ;

Anami, Katsuhiro ;

Schetter, Aaron J. ;

Moehler, Markus ;

Okayama, Hirokazu ;

Khan, Mohammed A. ;

Bowman, Elise D. ;

Mueller, Annett ;

Schad, Arno ;

Shimomura, Manabu ;

Hinoi, Takao ;

Aoyagi, Kazuhiko ;

Sasaki, Hiroki ;

Okajima, Masazumi ;

Ohdan, Hideki ;

Galle, Peter R. ;

Yasui, Wataru ;

Harris, Curtis C. .

INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (08) :1926-1934

[5]

Downregulation of miR-21 increases cisplatin sensitivity of non–small-cell lung cancer.[J].Liyun Xu;Yanyan Huang;Dongdong Chen;Jianying He;Wangyu Zhu;Yongkui Zhang;Xiaoguang Liu.Cancer Genetics.2014, 5

[6]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).[J].E.A. Eisenhauer;P. Therasse;J. Bogaerts;L.H. Schwartz;D. Sargent;R. Ford;J. Dancey;S. Arbuck;S. Gwyther;M. Mooney;L. Rubinstein;L. Shankar;L. Dodd;R. Kaplan;D. Lacombe;J. Verweij.European Journal of Cancer.2008, 2

[7]

银杏酚对顺铂化疗Heps肝癌小鼠血清干扰素-γ、白介素-2和肿瘤坏死因子-α水平的影响 [J].